Title

Vitamin D3 effects on lipids differ in statin and non-statin-treated humans: superiority of free 25-OH D levels in detecting relationships.

Journal

The Journal of clinical endocrinology and metabolism, 98(11)

ISSN

0021-972X

Authors

Kane, Lynn
Moore, Kelly
Lütjohann, Dieter
et al.

Publication Date

2013-11-01

DOI

10.1210/jc.2013-1922

Peer reviewed

Vitamin D3 effects on lipids differ in statin and non-statin treated humans: superiority of free 25-OH D levels in detecting relationships

Lynn Kane, R.N.[1]

Kelly Moore, Ph.D.[1]

Dieter Lütjohann, Ph.D[.2]

Daniel Bikle, M.D. Ph.D[3,4]

Janice B. Schwartz, M.D.[1, 35]

From the Jewish Home of San Francisco, CA[1,] Institute of Clinical Chemistry and Clinical Pharmacology, University Clinics of Bonn, Bonn Germany[2], and the Departments of Medicine[3] and Dermatology [4] and Bioengineering and Therapeutic Sciences,[5] University of California, San Francisco

Support: This study was funded in part by grants R01 AG 15982 and R56 AG15982, in part with resources of the Jewish Home of San Francisco, CA, by funds from Pfizer, Inc (Investigator-initiated Grant # WS526663) and by Grant Number UL1 RR024131 from the National Center for Research Resources

(NCRR)ClinicalTrials.gov Identifier: NCT00723385

Abbreviated title: vitamin D, lipids, and free 25-OH vitamin D

DISCLOSURE STATEMENT: The authors have nothing to disclose.

Address for correspondence and reprints: Janice B. Schwartz M.D., 302 Silver Avenue, San Francisco, CA 94112; Phone: 415-406-1573; Fax: 415-406-1577; Email: Janice.schwartz@ucsf.edu

Key words: Vitamin D, 25-OH vitamin D, free 25-OH vitamin D, lipids, HMG CoA reductase inhibitor, statin, atorvastatin

Word Count : manuscript: 3995 References: 40; Figures:4; Tables: 2 and four on-line Tables

ABSTRACT

Context: Inverse associations between 25-OH vitamin D levels and cardiovascular morbidity and mortality have been reported.

Objectives: To 1) investigate effects of correcting inadequate D status on lipids, 2) determine whether free 25-OH D is better correlated with lipids than total 25-OH D.

Design: Randomized, double-blind placebo-controlled trial

Setting: General community

Participants: D3 group: 14 men, 12 women, age 60 ± 8y (mean ±SD); placebo: 12 men, 11 women: 59 ±12y with inadequate D status

Intervention: 12 week oral vitamin D3 titrated (1000-3000 IU/day) to achieve 25-OH D levels $\geq$ 25 ng/mL compared to placebo.

Main Outcome Measures: 25-OH D (tandem mass spectometry), free 25-OH D (direct immunoassay), lipids (directly measured triglyceride, cholesterol and subfractions; plant sterols and cholesterol synthesis precursors), and safety labs before and after 6 and 12 weeks D3 or placebo. Data were analyzed by repeated measures ANOVA and linear regression.

Results: Vitamin D3 was titrated to 1000 IU/day in 15/26 (58%), to 2000 IU/day in 10 and 3000 IU/day in one. D3 had no effect on cholesterol or cholesterol subfractions except for decreases in atorvastatin-treated patients (cholesterol, p=.08; LDL-cholesterol, p=.05). Decreased campesterol concentrations (p=.05) were seen with D3 but not placebo in statin-treated patients. Relationships between total 25-OH D and lipids were not detected, *but*, inverse linear relationships were detected between free25-OH D and triglycerides (p=.03 for all participants (n=49), p=.03 in all statin-treated (n=19) and p=.0009 in atorvastatin-treated (n=11), and between free 25-OH D and LDL-cholesterol (p=.08 overall, p=.02 in all statin-treated and p=.03 for atorvastatin-treated), and total cholesterol (p=.09 overall; p=.04 for all statin-treated and p=.05 for atorvastatin-treated).

Conclusions: Vitamin D lipid lowering effects appear limited to statin-treated patients and are likely due to decreased cholesterol absorption. Relationships between lipids and D metabolites were only detected when free 25-OH D was measured suggesting the superiority of determining free 25-OH D levels compared to total 25-OH vitamin D levels when analyzing biologic responses.

INTRODUCTION

A role for vitamin D in the atherosclerotic process has been hypothesized as serum vitamin D levels have been inversely correlated with the degree of coronary artery calcification as determined by cardiac computed tomography, prevalence of hypertension, diabetes, obesity, high serum triglyceride levels, and cardiovascular and overall mortality. [1-4] The underlying mechanism of such benefits has not been established.

We previously investigated the effects of oral vitamin D supplementation (800 IU /day: 400 IU D3 and 400 IU D2 as part of multivitamins and combined with calcium) in patients receiving atorvastatin in an open label cross-over study. [5] Although not an entry criteria for our study, most participants were vitamin D deficient in the absence of supplementation. We hypothesized that CYP3A-metabolized atorvastatin concentrations would decrease during vitamin D supplementation and that cholesterol levels would rise. We found the hypothesized decrease in atorvastatin concentrations during vitamin supplementation but unexpectedly, LDL-cholesterol and total cholesterol were significantly lower during combined atorvastatin and vitamin D administration despite lower atorvastatin concentrations. The findings suggested a vitamin D effect on cholesterol metabolism or transport.

Strong cross-sectional associations between higher 25-OH vitamin D levels and lower total cholesterol, lower LDL cholesterol, higher HDL cholesterol and lower triglycerides have been reported from a large community database with a longitudinal analysis that showed increasing 25-OH D levels affected total and HDL-cholesterol levels but not LDL-cholesterol and triglyceride levels. [6] Prospective data on effects of vitamin D on lipids are limited with differing results in those that have been reported. [7-14] Vitamin D has been reported to lower triglyceride levels and to a lesser extent cholesterol concentrations as well as having no effect on these measures in small studies that largely lacked blinding or placebo groups. [7-14] The studies used relatively low doses of oral vitamin D3 (300-1000 IU/day), oral 1a,25-$(OH)_2$ vitamin D or i.v. 1a,25-$(OH)_2$ vitamin D for relatively short periods of time and only one assessed circulating vitamin D responses (with non-standardized assays).

A more recent study of weekly 50,000 IU D3 for 8 weeks in middle-aged men and women with baseline vitamin D deficiency and at risk of cardiovascular disease. This study reported no significant effects on total cholesterol, LDL-cholesterol, small LDL particle number, HDL-cholesterol or triglycerides with mean 25-OH vitamin D levels of 43 ± 12/3 ng/mL. wIncreases in calcium were positively related to LDL-cholesterol and inversely to serum parathyroid hormone. [15] These data suggest a potentially negative clinical effect of vitamin D supplementation on LDL-cholesterol.

Our primary goal in the current investigation was to determine effects of individual D3 dose titration with daily oral D3 to correct vitamin D inadequate states on lipid profiles. A secondary goal was to determine the relationship between free 25-OH vitamin D and lipid concentrations.

METHODS

Overall Design. This was a twelve week double-blind placebo-controlled dose titration study of the effects of D3 on lipid levels.

Subject selection. Subjects were vitamin D deficient (see below) adults able to provide informed consent, able to take oral non-crushed pills/capsules, clinically stable (no changes in medications/diagnoses within a month, or hospitalization within 6 months), no severe renal disease (eGFR≥28 ml/min/m2), no hypercalcemia or history of hypercalcemia, no history of recent renal stones or sarcoid, no history of osteoporotic fracture, or uncontrolled thyroid or parathyroid disorder, or intestinal bypass surgery or resection of small bowel, granulomatous disease, active malignancy other than non-melanoma skin cancer, detectable viral load if (HIV-infected), hematocrit <30% for women or <34% if men) or contraindications or allergy to vitamin D.

Subject Enrollment. After informed consent was obtained for the protocol approved by the University of California, San Francisco Committee on Human Research, demographic and medical data were collected including age, sex, race, height, weight, body mass index (BMI), renal status (eGFR), and disease states (bone disease (osteopenia, osteoporosis, fractures), cardiovascular disease, diabetes, thyroid, cancer, gastric resection, history of malabsorption disease), concomitant medications,

nutraceuticals, and sun exposure assessed with a sunshine questionnaire. [16] Blood was drawn on two baseline occasions at least one week apart to confirm vitamin D deficiency (25-OH vitamin D levels <25 ng/mL, Mayo Clinical Laboratories, Rochester, MN, http://www.mayomedicallaboratories.com/). Additional tests included creatinine, calcium, phosphorus, HgbA1c (in diabetics), HIV viral load (in HIV-positive subjects taking protease inhibitors) and fasting complete lipid profile, LDL and HDL subfractions, VLDL and/or lipoprotein (a) concentrations, triglycerides (VAP test, Atherotech Diagnostics Lab, Birmingham, AL, http://www.atherotech.com). Enrollment was concentrated in spring and summer (84% of participants).

Randomization, Study conduct. and Vitamin D Dose Titration. Subjects were randomized to vitamin D3 1000 IU/day (one capsule) or matching placebo, stratified by sex and instructed to take capsules with the fattiest meal of the day. Subjects with severe vitamin D deficiency (<10 ng/mL) were not randomized but could be assigned to 1000 IU/day D3. Subjects were interviewed every two weeks for health status (illnesses, \ physician visits, medication changes, self-reported health status, side effects), and study-related dispensing. After 6 and 12 weeks, fasting blood samples were obtained for 25-OH vitamin D, calcium, lipids, and weight and blood pressure, measured. Dosing was: 1) Vitamin D3 group a) with baseline 25-OH vitamin D concentrations of ≤20 ng/mL, doses were increased to 2000 IU/day (two 1000 IU capsules) if 25-OH D concentrations at week 6 were <25 ng/mL. Doses remained at 1000 IU/day (one 1000 IU and one placebo capsule) for weeks 7-12 if measured 25 OH-D was ≥25 ng/mL. 2) For those with baseline 25-OH vitamin D concentrations of 21-25 ng/mL, D3 dose was increased to 2000 IU/day if 25-OH vitamin D level was not increased at least 25% over baseline after six weeks or remained at 1000 IU/day (plus matching placebo) for weeks 7-12 if 25-OH D increased greater than 25 per cent of baseline. After 12 weeks, if target 25-OH D levels were not reached, subjects could enroll in a six week open label extension and receive 3000 IU/day. 2) Placebo group. Subjects randomized to placebo received one placebo capsule during weeks 1-6 and two placebo capsules for weeks 7-12.

Vitamin D formulations. D3 (cholecalciferol) and matching placebo were obtained from Bio-Tech Pharmacal, Inc (Fayetteville, Arkansas, www.Bio-Tech-Pharm.com) with validated vitamin D content at formulation, and after 1 and 2 years. Independent content analysis was performed before dispensing, and every 12 weeks thereafter. (Tai C. Chen, Ph.D., CTSI, Boston University)

Testing Procedures/Measurements

25-OH Vitamin D3 + D2 Measurements were determined by CLIA certified liquid chromatography tandem mass spectrometry at Mayo Clinical Laboratories with participation in ODS-funded NIST quality assurance program for analysis of vitamin D metabolites in human serum. The assay has ~10% CV at levels <10 ng/mL. Internal standard is NIST reference standard.

Free (unbound) 25-OH vitamin D concentrations were determined by immunoassay (Future Diagnostics B.V., Wijchen, The Netherlands, http://www.future-diagnostics.nl/) [17]

D3 capsule content. Analyses of capsule content were performed by HPLC after saponification and correction of the yield according to recovery of added external D3 (NIST) standard (Tai C. Chen, Ph.D., CTSI, Boston University). [18, 19]

Dietary vitamin D intake Dietary vitamin D and cholesterol intake was estimated by Block 2005 Food Frequency l questionnaire (NutritionQuest, Berkeley, CA). [20]

Lipid and cholesterol subfraction concentrations (total and cholesterol-r(eal), LDL and subfractions, HDL and subfractions, VLDL and/or lipoprotein (a) concentrations, triglycerides were determined. (Atherotech Diagnostics Lab, Birmingham, AL, http://www.atherotech.com). [21]

Total plasma cholesterol precursor lathosterol and the plant sterol campesterolwere were determined by gas chromatography-mass spectrometry-selected ion monitoring (GC-MS-SIM) using epicoprostanol as internal standard. Cholesterol was measured from the same plasma sample by GC-flame ionization detection (GC-FID) using 5α-cholestane as internal standard. [22, 23]

Safety measures. Calcium, phosphorus, creatinine, and HgbA1c were performed by Quest Diagnostics, San Jose, CA (http://www.questdiagnostics.com). HIV viral copy number was performed

in clinical laboratories of San Francisco General Hospital, San Francisco, CA. (http://labmed.ucsf.edu/sfghlab/)

Other Measurements. Weight and height were measured using balance beam scale. Body mass index was calculated (weight (kg) divided by height^2 (M)). Blood pressure and heart rate were measured using automated aneroid devices.

Adherence was determined from pill counts o.

Statistical Design and Data Analysis. Demographic and baseline characteristics of groups are presented as mean ± S. D. and compared using ANOVA or Kruskal-Wallis for continuous variables, as appropriate, and Chi-square tests for categorical variables. Effects of D3 compared to placebo were determined by repeated measures ANOVA. A priori sample size estimates for the main effect (vitamin D vs. placebo) were based on our prior report [5] with an effect size of 0.3, intracluster correlations of 0.5 and analysis by repeated measures ANOVA with alpha=.095, beta=0.8, yielding an estimated total sample of 58. Relationships between total or free, unbound 25-OH vitamin D and lipid concentrations were tested by linear regression.

ClinicalTrials.gov. The study was registered with clinicaltrials.gov as NCT 00723385

RESULTS

Subjects. Fifty-six subjects had total 25-OH D levels <25 ng/mL on initial screening with two ineligible due to 25-OH D concentrations ≥ 25 ngl/mL on repeat baseline measurement. Fifty-four subjects underwent randomization stratified by sex and season; there was one subject dropout due to physical relocation and four were removed due to study non-adherence (sunburn at visits, stated non-adherence with capsule intake, stated significant change in diet). Data were analyzed for forty-nine subjects (a priori power calculations for this sample size estimates power of avoiding a type II error of 0.7). Twenty-six received vitamin D3 (14 men and 12 women; 19 Caucasian, 5 African American, 2 Asian) and 23 received placebo (twelve men and 11 women; 15 Caucasian, 6 African American, 1 Asian, 1 other). Subject characteristics are summarized in Table 1. The D3 and placebo group were

similar in age, weight, medical status, renal status, estimated dietary intake of D, estimated sun exposure, and baseline 25-OH vitamin D levels. There were few smokers (two in the vitamin D group reporting smoking about one-half pack/day and 4 in the placebo group reported smoking about 1 pack/day) and more subjects reported alcohol intake in the vitamin D3 group. Of the 17 in the D3 group reporting alcohol consumption, 5 consumed it daily and twelve less frequently (8 on a weekly basis, 3 on a monthly basis and one annually). For the 10 placebo group subjects reporting alcohol consumption, consumption was daily in 2 and less frequently in ten (weekly in 4, monthly in 4 and once yearly in two). One woman in the D3 group took birth control pills (estrogen and progesterone)., No other sex hormones were taken. Other medications taken by >2 subjects per group were: HMG CoA reductase inhibitors (D3 group n=9, placebo n=10; more frequent in diabetics than non-diabetis ($p<.001$) , diuretics (D3 n=7, placebo n=4; more frequent with hypertension ($p<.001$)), ACE inhibitors (D3 n=4, placebo n=7); aspirin (D3 n=5, placebo=6), NSAID's (D3 n=4, placebo =1), thyroid (D3 n=4, placebo n=5), insulin (D3 n=3, placebo n=1), proton pump inhibitors (D3 n=3, placebo n=3) .

Study Capsule Content. Mean content of capsules during the period subjects received capsules was 917 ± 168 IU/capsule.

Vitamin D3 doses and Resultant 25-OH Vitamin D Concentrations (see Table 2). Final vitamin D3 doses were 1000 IU/day (25 mcg/day) in 15/26 (58%), 2000 IU/day (50 mcg/day) in 10 (38%), and 3000 IU/day (75 mcg/day) in one. Dietary vitamin D intake did not differ between groups titrated to 1000 or 2000 IU/day (110 ±71 and 84 ± 28 IU/day, respectively). The D3 dose to achieve target 25-OH D levels was positively related to weight ($p<.03$) and BMI ($p<.008$), and higher in subjects with hypertension ($p<0.05$) and/or receiving diuretics ($p<.06$). Diuretics were used in all but one subject with hypertension so effects of hypertension or diuretic use could not be distinguished. No effect of age, diabetes, statin intake, thyroid disease, heart failure, ACE inhibitors, aspirin or NSAID's, smoking status, alcohol intake, or season of enrollment and participation was detected on dose requirements to reach target 25-OH vitamin D concentrations.

At study end, 25-OH vitamin D concentrations were about double baseline values in the vitamin D3 group (from 16.2 ±4.5 to 32.7 ± 6.2 ng/mL. p<.0001) and unchanged in the placebo group (f 16.7 ±4.4 ng/mL at entry and 17.9 ±8.3 at study end). Free 25-OH vitamin D levels at baseline ranged from 1.7 to 4.5 pg/mL and undetectable in one participant. Free 25-OH levels increased with D3 to a mean of 5.7 ±1.1 pg/mL (p<.0001; range 1.6 to 7.9 pg/mL) at study end and were unchanged with placebo (see Table 2). 25-OH vitamin D2 levels were detectable in 4 subjects at baseline (3 assigned to D3 and 1 assigned to placebo) and two at study end (both assigned to placebo).

Lipid Responses by Group Assignment. Vitamin D3 did not significantly affect lipids or cholesterol subfractions of LDL and HDL, IDL, LDL-R-c, remnant fractions). Total cholesterol, LDL-cholesterol, HDL-cholesterol, VLDL-cholesterol, Lipoprotein (LP)a and triglyceride concentrations for vitamin D3 and placebo are shown in on-line Tables 1 and 2 . As results differed from our observation in patients receiving vitamin D with atorvastatin, responses of atorvastatin treated participants (D3 group n=5 receiving 45 ±25 mg/day; placebo, n=6 receiving 43 ±27 mg/day) were analyzed. Lipid concentrations were lower in patients receiving atorvastatin compared to those not receiving atorvastatin throughout (repeated measures ANOVA, p<.001). Vitamin D3 in the atorvastatin-treated patients lowered total cholesterol 12% (p=.06) and LDL-cholesterol 14% (p=0.05) compared to placebo (Figure 1).

To investigate potential underlying mechanisms for decreases in LDL-cholesterol, surrogate serum markers of cholesterol absorption (campesterol) and endogenous whole body cholesterol biosynthesis, (lathosterol) were examined in the statin-treated participants (n=21, 19 completed the study and two with baseline and midstudy data) and a subset (n=6) of non-statin treated participants for whom serum were available. Results are presented in Fig 2 and on-lineTable 3. Campesterol concentrations were lower after D3 administation in statin-treated patients compared to baseline (from 0.710 ±0.41 to 0.582±0.31) while unchanged in the statin-treated group that received placebo (0.408 ±0.186 and 0.408 ±0.173, p=0.05 for the D3 and campesterol interaction, repeated measures AN0VA). The decrease in the ratio of campesterol to cholesterol in the D3 treated compared to placebo did not

reach significance (p=0.12). No D3 vs. placebo treatment effects were detected on lathosterol concentrations. In D3 treated subjects not receiving statins, lathosterol concentrations were higher than statin-treated subjects (p=.001) but neither lathosterol or campesterol concentrations were affected by vitamin D3 administration.

Relationships between total or free 25-OH vitamin D and Lipids. No relationships were detected between circulating total 25-OH vitamin D levels and lipid levels (triglyceride (p=.62), cholesterol (p=.67), LDL-cholesterol (p=.52) or HDL-cholesterol (p=0.76). In contrast, relationships were detected between free 25-OH vitamin D concentrations and lipid parameters with D3 administration but with placebo administration. Relationships for total cholesterol, LDL-cholesterol and triglycerides and free 25-OH concentrations at baseline and at study end for the placebo and vitamin D groups are presented in Figure 3. No significant relationships were detected at baseline but after vitamin D3 administration, inverse relationships for LDL-cholesterol and free 25-OH vitamin D were significant (p=.009), and approached significance for total cholesterol (p=.07). No relationships between free 25-OH vitamin D and lipids were detected in the placebo group.

Relationships between free 25-OH vitamin D levels and total and LDL_cholesterol and triglycerides were also examined for statin- treated participants. Individual data are in Figure 4. As more participants received atorvastatin than other statins (none on pravastatin, and one on lovastatin) and randomization was not stratified by statin, relationships were largely determined by atorvastatin participants. Inverse relationships were significant for free 25-OH vitamin D and triglycerides (atorvastatin users p=0.0009, all statin users, p=0.03), total cholesterol (atorvastatin users p=0.05; all statin users, p=.04), and for LDL-cholesterol (atorvastatin users p=.03 all statin users, p=0.02). For HDL-cholesterol, no relationships were detected for all statin-treated (0.186), with a possible trend for a positive relationship in atorvastatin-treated subjects (r^2=0.145, p=0.07).

Safety measures. Calcium concentrations did not change with D3 or placebo (Table 2) nor did phosphorus or creatinine change (data not shown). HgbA1c in diabetics (n=4 D3 group, n=5 placebo) was not altered during the study. Five HIV-infected with undetectable viral load on protease inhibitors

had viral load undetectable throughout except for a blip at mid-stud (60 detectable copies) in one with return to non-detectable at twelve weeks.

Vital Signs. Weight and heart rate were unchanged during the study. Systolic and blood pressure decreased slightly but significantly ($p<.04$) for both the placebo and vitamin D group; from 128 ± 21 mmHg to 123 ± 15 after 6 weeks and 124.8 ±22 mmHg in the D3 group and from 125 ±15 mmHg to 118 ±14 after 6 weeks and 124 ± 17 mmHg after 12 weeks in the placebo group.

Adherence. Mean adherence was 98 ±6 % in the vitamin D3 group and 97 ±7% in the placebo group.

DISCUSSION

Vitamin D plays a role in the regulation of hundreds of genes involved in bone and mineral metabolism, the renin-angiotensin–aldosterone system, the immunologic system, the cardiovascular system, muscle metabolism and strength, cellular proliferation and differentiation and survival of cells in disorders such as cancer. [24-26] With increased recognition of the role of vitamin D in health and disease has come the incentive to assure adequate vitamin D status in people.

We investigated effects of administering vitamin D3 to correct vitamin D inadequacy on lipid concentrations. Based on our prior observations that LDL-cholesterol and total cholesterol were significantly lower during combined atorvastatin and vitamin D administration compared to atorvastatin without D supplementation, we hypothesized that cholesterol concentrations would be lower after vitamin D supplementation. We chose a dose titration to a target 25-OH vitamin D concentration strategy and began titration with 1000 IU/day vitamin D3 as previously 800 IU/day vitamin D did not achieve 25-OH D concentrations over 20 ng/mL in one third of subjects. [5] In this study, three participants (of 26 assigned to D3) did not increase concentrations above 20 ng/mL with 1000 IU/day D3 and slightly over one third of subjects did not achieve concentrations above 25 ng/mL. With 2000 IU/day, all but one very obese subject achieved 25-OH D concentrations over 25 ng/mL.

We detected no effect of vitamin D3 supplementation and increased total circulating 25-OH vitamin D concentrations on cholesterol, cholesterol subfractions, or triglyceride measurements in the

total group of subjects randomized to vitamin D3 compared to those randomized to placebo. These results are in agreement with conclusions from a recent meta-analysis of randomized studies of effects of varying doses of vitamin D on lipids. [27] The randomized double-blind placebo-controlled studies included in the meta-analysis excluded patients receiving statins leaving the question of the effects of vitamin D supplementation in the large number of people receiving statins with inadequate vitamin D status unanswered. [28] Importantly, we found a lowering of LDL-cholesterol and total cholesterol in patients receivingstatins with correction of vitamin D inadequacy and identified a potential mechanism for lipid lowering in these statin-treated patients. The decreases in LDL-cholesterol in atorvastatin-treated patients with baseline vitamin D inadequacy were of the same magnitude of 12-14% as our results in a different group of atorvastatin-treated patients. [5] Potential explanations include vitamin D or vitamin D metabolite direct effects on cholesterol metabolism – either decreases in absorption or decreases in endogenous cholesterol synthesis. In vitro, vitamin D has been reported to inhibit HMG-CoA reductase in cultured human skin fibroblasts, transformed human liver cells and mouse peritoneal macrophages and to inhibit lanosterol-14-α demethylase (CYP51A1) involved in cholesterol biotransformation. [29] The lack of effect of vitamin D3 to lower cholesterol in non-statin treated participants in our studies and those of others argues against a clinically relevant inhibition of HMG Co-A reductase or cholesterol biotransformation.

In humans, while statins inhibit cholesterol synthesis they also upregulate cholesterol absorption. [30, 31] Cholesterol balance studies of cholesterol synthesis and intestinal cholesterol absorption have demonstrated that the plasma sterol campesterol can serve as a marker of fractional cholesterol absorption and the plasma sterol lathosterol as a surrogate serum marker of endogenous whole body cholesterol biosynthesis. [32] We found campesterol concentrations decreased in statin-treated participants after vitamin D3 administration compared to statin-treated participants receiving placebo that had no changes in campesterol concentrations. Furthermore, no effect of vitamin D3 administration on campesterol

concentrations was seen in non-statin treated participants. We also failed to find any effect of vitamin D3 on lathosterol concentrations compared to placebo administration. The lack of changes in lathosterol argue against a decrease in cholesterol synthesis either by direct effects or due to indired vitamin D immunomodulatory and cytokine suppressive effects [33]. The data suggest that decreased cholesterol absorption contributed to reduced LDL and total cholesterol concentrations in response to vitamin D in the statin-treated participants. Inhibition of cholesterol absorption would be predicted to be greatest in atorvastatin-treated participants as atorvastatin has greater effects on increasing cholesterol absorption compared to simvastatin (or rosuvastatin). [30, 31] A vitamin D3 effect to decrease cholesterol absorption might also have been undetected in people not receiving lipid lowering therapy as dietary absorption contributes less to circulating cholesterol levels than endogenous production. It is also plausible that D3 effects on lipids might only be seen in patients with underlying abnormal lipid metabolism or metabolic disorders such as hypercholesterolemia or diabetes.

A unique aspect of our work is that we analyzed responses of lipid parameters in relation to circulating free as well as total 25-OH vitamin D concentrations, and in subgroups receiving or not receiving statins. We failed to detect relationships between total 25-OH vitamin D concentrations and lipids or lipid subfractions. Variation in vitamin D binding protein levels and properties affect levels of the free fraction of circulating 25-OH vitamin D available to be converted to the active $1\alpha,25\ (OH)_2$ vitamin D moiety. [34-38] If vitamin D actions are similar to that of other hormones such as testosterone, free concentrations may be more relevant to biologic responses. In support of this hypothesis, it has been recently reported that free 25-OH vitamin D concentrations are more closely related to iPTH concentrations than total 25-OH vitamin D circulating concentrations in renal failure patients. [39] At baseline, free 25-OH vitamin D concentrations were low and not detectable in some subjects. With D3 supplementation, free 25-OH vitamin D concentrations increased, and inverse relationships between free 25-OH vitamin D concentrations and triglycerides, cholesterol and LDL-

cholesterol became apparent. These clinically favorable trends were seen in the vitamin D treated group as a whole and were significant in the statin treated participants, especially for triglycerides in atorvastatin-treated subjects. Effects may have been more apparent in atorvastatin treated subjects as there were more participants on atorvastatin than other statins, or because diabetics that are more likely to have abnormalities in lipid and triglyceride metabolism received atorvastatin than other statins. These data indicate the potential utility of free 25OH vitamin D measurements when assessing biologic actions *in vivo*.

There are potential limitations to our study. The duration was relatively short although adequate to reach steady-state circulating 25-OH vitamin D levels [40] and we did not study lower dosages previously shown to be inadequate, or higher weekly replacement regimens used in severe vitamin D deficiency. The study could not fully investigate the full spectrum of lipid effects in the statin-treated subgroup or investigate individual statins prospectively. Circulating vitamin 1,25-OH_2 D levels were not measured as changes in circulating concentrations are not seen during vitamin D supplementation despite changes in 25-OH vitamin D and may not reflect conversion to active 1,25 OH_2 D in tissues. Results were obtained from subjects with limited and constant sun exposure representative of most adults using sun protection but may not reflect requirements of those with significant sunshine or UV exposure. Extrapolation to recommendations for commercial formulations may not be exact as commercial preparations may not have s labeled content.

In summary, our data support the existence of an interaction of vitamin D3 with lipids in HMG CoA reductase (stain) treated patients in directions that would be clinically favorable and that a contributing underlying mechanism is likely to be reduced cholesterol absorption. The data further suggest that this interaction is better demonstrated with free 25-OH vitamin D measurements than with total 25-OH vitamin D measurements. The results warrant further study.

ACKNOWLEDGEMENTS

This study and its contents are solely the responsibility of the author and do not necessarily represent the official view of NCRR of NIH. Information on NCRR is available at http://www.ncrr.nih.gov/. Information on Re-engineering the Clinical Research Enterprise can be obtained from http://nihroadmap.nih.gov/clinicalresearch/overview-translational.asp. The work could not have been completed without the assistance of the staff of the Jewish Home San Francisco, and the assistance of Seniors At Home of the Jewish Family and Childrens Services, San Francisco. We are grateful to the technical assistance of Anja Kerksiek, Institute of Clinical Chemistry and Clinical Pharmacology, University of Bonn, Germany.

REFERENCES

1. Martins D, Wolf M, Pan D, Zadshi A, Tareen N, Thadhani R, Felsenfeld A, Levine B, Mehrotra R, Norris K: Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States. Data from the Third National Health and Nutrition Examination Survey *Arch Intern Med* 2007, 167:1159-1165.

2. Michos E, Blumenthal R: Vitamin D supplementation and cardiovascular disease risk. *Circulation* 2007, 115:827-828.

3. Autier P, Gandini S: Vitamin D supplementation and total mortality. A meta-analysis of randomized controlled trials. *Arch Intern Med* 2007, 167:1730-1737.

4. McGreevy C, Williams D: New insights about vitamin D and cardiovascular disease. A narrative review. *Ann Intern Med* 2011, 155:820-826.

5. Schwartz J: Effects of vitamin D supplementation in atorvastatin treated patients: a new drug interaction with an unexpected consequence. *Clin Pharmacol Ther* 2009, 85(2):198-203.

6. Ponda MP, Huang X, Odeh MA, Breslow JL, Kaufman HW: Vitamin D may not improve lipid levels: a serial clinical laboratory data study. *Circulation* 2012, 126:270-277.

7. Carlson LD, H, Lanner A: Effect of different doses of vitamin D on serum cholesterol and triglyceride levels in health men. *Atherosclerosis* 1970, 12(2):313-317.

8. Gannage-Yared M, Azoury M, Mansour I, Baddoura R, Halaby G, Naaman R: Effects of a short-term calcium and vitamin D treatment on serum cytokines, bone markers, insulin and lipid concentrations in healthy post-menopausal women. *J Endocrinol Invest* 2003, 26(8):748-753.

9. Adams C, Reitz J, De Brabander J, Feramisco J, Li L, Brown M, Goldstein J: Cholesterol and 25-Hydroxycholesterol Inhibit Activation of SREBPs by Different Mechanisms, Both Involving SCAP and Insigs* *J Biol Chem* 2004, 279(50):52772-52780.

10. Carbone L, Rosenberg E, Tolley E, Holick M, Hughes T, Watsky MB, KD, Chen T, Wilkin N, Bhattacharya S, Dowdy J *et al*: 25-Hydroxyvitamin D, cholesterol, and ultraviolet irradiation. *Metabolism Clinical and Experimental* 2008, 57:741-748.

11. Heikkinen A-M, Tuppurainen M, Niskanen L, Komulainen M, Penttila I, Saarikoski S: Long-term vitamin D3 supplementation may have adverse effets on serum lipids during postmenopausal hormone replacement thereapy. *Eur J Endocrinolog* 1997, 137:495-502.

12. Mak R: 1,25-dihydroxyvitamin D3 corrects insulin and lipid abnormalities in uremia. *Kidney International* 1998, 53:1353-1357.

13. Maung K, Miyazaki A, Normiyama H, Chang C, Chang T, Horiuchi S: Induction of acyl-coenzyme A:cholesterol acyltransferase-1 by 1,25-dihydroxyvitamin D(3) or 9-cis-retinois acid in undifferentiated THP-1 cells. *J Lipid Res* 2001, 42(2):181-187.

14. Major G, Alarie F, Doré J, Phouttama S, Tremblay A: Supplementation with calcium + vitamin D enhances the beneficial effect of weight loss on plasma lipid and lipoprotein concentrations. *Am J Clin Nutr* 2007, 85(1):54-59.

15. Ponda M, Dowd K, Finkielstein D, Holt P, Breslow J: The short-term effects of vitamin D repletion on cholesterol: a randomized, placebo-controlled trial. *Arterioscler Thromb Vasc Biol* 2012, 32(10):2510-2515.

16. Kampman E, Slattery M, Caan B, Potter J: Calcium, vitamin D, sunshine exposure, dairy products and colon cancer risk (United States). *Cancer Causes and Control* 2000, 11:459-466.

17. Swinkels L, Maas A, Martens M, Parsons G, Rosmalen F: An immunoassay for Free 25-Hydroxy vitamin D. In: *43rd Oak Ridge Conference Emerging Techologies for 21st Century Diagnostics: April 14-15 2011; Baltimore, MD*; 2011.

18. Byrdwell W, DeVries J, Exler J, Harnly J, Holden J, Holick M, Hollis B, Horst R, Lada M, Lemar L *et al*: Analyzing vitamin D in foods and supplements: methodologic challenges. *Am J Clin Nutr* 2008, 88 (suppl):554S-557S.

19. Chen T, Turner A, Holick M: A method for the determination of the circulating concentration of vitamin D. *J Nutr Biochem* 1990, 1:272-276.

20. Block G, Hartman A, Naughton D: A reduced dietary questionnaire: development and validation. *Epidemiology* 1990, 1(1):58-64.

21. Kulkarni K: Cholesterol Profile Measurement by Vertical Auto Profile Method *Clin Lab Med* 2006, 26:787-802.

22. Lütjohann D, Brzezinka A, Barth E, Abramowski D, Staufenbiel M, von Bergmann K, Beyreuther K, Multhaup G, Bayer TA: Profile of cholesterol-related sterols in aged amyloid precursor protein transgenic mouse brain. *J Lipid Res* 2002, 43(7):1078-1085.

23. Teunissen CE, Mulder M, de Vente J, von Bergmann K, De Bruijn C, Steinbusch HW, Lütjohann D: Concentrations of different sterols in the striatum and serum of 3-nitropropionic acid-treated Wistar and Lewis rats. *Neurochem Res* 2001, 26(11):1237-1244.

24. Holick M: Vitamin D Deficiency. *N Engl J Med* 2007, 357:266-281.

25. Bikle D: Nonclassic actions of vitamin D. *J Clin Endocrinol Metab* 2009, 94(1):26-34.

26. Bikle D: Vitamin D: newly discovered actions require reconsideration of physiologic requirements. *Trends Endocrinol Metab* 2010, 21(6):375-384.

27. Wang H, Xia N, Yang Y, Peng D-Q: Infuence of vitamin D supplementation on plasma lipid profiles: A meta-analysis of randomized controlled trials. *Lipids in Health and Diseae* 2012, 11:42-50.

28. Jorde R, Grimnes G: Vitamin D and lipids: do we really need more studies? *Circulation* 2012, 126:252-254.

29. Gupta A, Sexton R, Rudney H: Effect of vitamin D3 derivatives on cholesterol synthesis and HMG-CoA reductase activity in cultured cells. *J Lipid Research* 1989, 30:379-386.

30. Miettinen TA, Gylling H, LIndbohm N, Miettinen TE: Serum noncholesterol sterols during inhibition of cholesterol syntheseis by statins. *J Lab Clin Med* 2003, 141:131-137.

31. van Himbergen TM, Matthan NR, Resteghini NA, Otokozawa S, Ai M, Stein EA, Jones PH, Schaefer EJ: Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis an absorption markers. *J Lipid Res* 2009, 50:730-739.

32. Miettinen TA, Tilvis RS, Kesaniemi YA: Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. *Am J Epidemiol* 1990, 131:20-31.

33. Hart PH, Gorman S, Finlay-Jones JJ: Modulation of the immune system by UV radiation: more than just the effects of vitamin D? *Nature Reviews* 2011, 11:585-589.

34. Bikle D, Gee E, Halloran B, Kowalski M, Ryzen E, Haddad J: Assessment of the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the vitamin D-binding protein. *J Clin Endocrinol Metab* 1986, 63:954-959.

35. Fu L, Yun F, Oczak M, Wong B, Vieth R, Cole D: Common genetic variants of the vitamin D binding protein (DBP) predict differences in response of serum 25-

414 hydroxyvitamin D [25(OH)D] to vitamin D supplementation. *Clin Biochem* 2009,
415 42:1174-1177.
416 36. Adams J, Hewison M: Update in vitamin D. *J Clin Endocrinol Metab* 2010, 95(2):471-
417 478.
418 37. Christakos S, Hewison M, Gardner DG, Wagner CL, Sergeev IN, Rutten E, Pittas AG,
419 Boland R, Ferrucci L, Bikle DD: Vitamin D: beyond bone. *Ann N Y Academy Sci* 2013,
420 1287 45-58.
421 38. Lisse T, Hewison M, Adams J: Hormone response element binding proteins: novel
422 regulators of vitamin D and estrogen signaling. *Steroids* 2011, 76(4):331-339.
423 39. Bhan I, Powe CE, Berg AH, Ankers E, Wenger JB, Karumanchi SA, Thadhani RI:
424 Bioavailable vitamin D is more tightly linked to mineral metabolism than total vitamin D
425 in incident hemodialysis patients. *Kidney International* 2012, 82:84–89.
426 40. Holick M, Biancuzzo R, Chen T, Klein E, Young A, Bibuld D, Reitz R, Salameh W,
427 Ameri A, Tannenbaum A: Vitamin D2 is as effective as vitamin D3 in maintaining
428 circulating concentrations of 25-hydroxyvitamin D. *J Clin Endocrinol Metab* 2008,
429 93:677-681.
430

FIGURE LEGENDS

Figure 1. Mean (± S.E.) cholesterol responses to daily oral vitamin D3 administration (solid circles connected by solid lines) or placebo (open circles connected by dashed lines) at baseline, after at least 6 weeks (mid-study) and at least 12 weeks (Study End) in atorvastatin-treated participants are shown in the upper panel and responses of LDL-cholesterol are shown in the lower panel. Differences in responses were significant ($p<.05$)

Figure 2. Mean (± S.E.) campesterol responses (upper panel) and lathosterol responses (lower panel) to daily oral vitamin D3 administration (solid circles connected by solid lines) or placebo (open circles connected by dashed lines) at baseline and study end for statin-treated participants are presented. Differences in campesterol responses between the D3 treated vs. placebo treated approached significance ($p=.05$)

Figure 3. Relationships between free 25-OH vitamin D concentrations and cholesterol (total), triglycerides, and LDL-cholesterol are presented for the D3- supplemented group at baseline (open circles, and dotted lines) and at the end of supplementation (closed circles and solid lines) in the left panels and for the placebo group at baseline (open triangles and dotted lines) and at the end of the study (closed triangles and solid lines) in the right panels. Regression results are presented with baseline values above the 0 point and relationships at study end toward the right of each panel. Significant relationships existed after D3 supplementation for LDL cholesterol ($p<.007$) and approached significance for total cholesterol, $p<.08$). At no time points were significant relationships detected in the placebo-treated subjects, likely due to the narrow range of free 25-OH D concentrations. No significant relationships at any time were detected for total 25-OH vitamin D concentrations and lipids (data not shown).

Figure 4. Relationships between circulating free 25-OH vitamin D concentrations and triglycerides, LDL cholesterol, and total Cholesterol are shown for the for the HMG CoA reductase inhibitor (statin) treated participants. Atorvastatin data are represented by solid circles , simvasatin data by open circles and lovastatin data by inverted triangles. Significant inverse relationships were detected between free 25-OH

vitamin D concentrations and triglycerides, LDL-cholesetrol and cholesterol concentrations (results are presented within the figures for atorvastatin-treated participants, see text for additional details).

Table
Click here to download Table: RevisedTable1.docx

Table 1 . Subject Characteristics at Baseline

	Vitamin D3 (n=26)	Placebo (n=23)	Between Group Difference
Age (y)	60 ± 8	59 ±12	ns
Weight (kg)	88.4 ± 24.4	82.7 ± 19	ns
Height (cm)	169.4 ± 9.1	165.2 ±9.4	ns
BMI (kg/m ^{2})	30.7 ± 7.6	30.4 ±7.4	ns
Creatinine (mg/dL)	1.0 ±0.4	0.9 ± 0.2	ns
eGFR (ml/min m ^{2})*	78 ± 22	82 ± 20	ns
Charlson Co-morbidity Score	3.4 ± 2.5	3.4 ± 4.1	ns
Diabetes	4	6	ns
Hypertension	11	14	ns
Coronary Artery Disease	4	4	ns
Heart failure	3	2	ns
Number of daily medications	5.2 ± 5.1	5 ± 5.5	ns
Receiving HMG CoA reductase inhibitor (n)	9	10	ns
Vitamin D from diet (IU/day)	111 ±74	128 ±74	ns
Estimated sun exposure/day (hr)	2.9 ±2.7	2.9 ±2.7	ns
Calcium (mg/dL)	9.4 ±0.4	9.5 ±0.4	ns
Serum 25- OH Vitamin D (ng/mL)	16.2 ± 4.5	16.7 ± 4.4	ns
Cigarette Smoker	2	4	
Alcohol Drinker	17	10	
Birth Control Pills	1	0	
Diuretic	7	4	

Data are mean ± S. D. * Modification of Diet in Renal Disease **(**MDRD**)** formula.

Table
Click here to download Table: Revised Table 2.docx

Table 2 . Responses to Vitamin D3 or Placebo

	Baseline	Mid-study	Study End	Between Group Differences in Responses*
Total 25-OH Vitamin D (ng/mL)				
Vitamin D3 Group	16.2 ± 4.5	28.2 ±6.1	32.7 ±6.2	p <.0001
Placebo Group	16.7 ± 4.4	18.2 ±7.1	17.9 ±8.3	
Free 25-OH Vitamin D3 (pg/mL)				
Vitamin D3 Group	2.9 ± 0.9	4.7 ± 1.1	5.7 ±1.1	p <.0001
Placebo Group	2.9 ± 0.7	3.2 ± 0.8	3.2 ± 1	
25-OH Vitamin D2 (ng/mL)				
Vitamin D3 Group	0.4 ±1.8	0.04 ± 0 0.1	0.5 ±2.1	ns
Placebo Group	0.5 ±2.2	0.8 ± 2.4	1.2 ±2.9	
Calcium (mg/dL)				
Vitamin D3 Group	9.4 ±0.4	9.4 ±0.4	9.3 ±0.4	ns
Placebo Group	9.4 ±0.4	9.3 ±0.5	9.3 ±0.4	

Data are mean ± S.D. * repeated measures ANOVA.

Figure

Click here to download Figure: Fig1-retry.ppt



Figure
Click here to download Figure: Final Fig 2.ppt



Fig 2

Figure

Click here to download Figure: Fig3--retry.ppt



Figure

Click here to download Figure: Final Fig 4.ppt